PMID- 15710172 OWN - NLM STAT- MEDLINE DCOM- 20050408 LR - 20151119 IS - 0041-008X (Print) IS - 0041-008X (Linking) VI - 203 IP - 2 DP - 2005 Mar 1 TI - Differences between rats and mice in the involvement of the aryl hydrocarbon receptor in 4-vinylcyclohexene diepoxide-induced ovarian follicle loss. PG - 114-23 AB - Repeated dosing with the occupational chemical 4-vinylcyclohexene diepoxide (VCD) selectively depletes small pre-antral follicles in the ovaries of rats and mice via apoptosis. The aryl hydrocarbon receptor (AhR) plays a role in mediating the effects of several xenobiotics. Therefore, this study was designed to investigate a potential role of the AhR in VCD-induced ovotoxicity. Female F344 rats, C57BL/6 mice, or AhR-deficient (-/-, AhRKO) mice were dosed daily (15 days) with vehicle, VCD (80 mg/kg, i.p.) and/or the AhR antagonist, alpha-naphthoflavone (ANF; 80 mg/kg, i.p.). Compared with controls, VCD caused a 60% reduction (P < 0.05) in primordial and primary follicles in mice and rats. Concurrent dosing with ANF protected against the VCD-induced follicle loss in rats, but not in mice. As with AhR-intact mice and rats, VCD induced a 70% loss (P < 0.05) of small pre-antral follicles in AhRKO mice. AhR mRNA expression was increased (P < 0.05) by VCD dosing in small pre-antral follicles isolated from ovaries of rats but not mice. AhR protein in rats was increased by VCD dosing in oocyte nuclei in primordial and primary follicles when measured by immunofluorescence and confocal microscopy. In rat small pre-antral follicles, apoptosis-associated caspase-3-like activity was increased (P < 0.05) by VCD treatment, decreased (P < 0.05) by ANF treatment, and unaffected by VCD plus ANF treatment. VCD had no effect on expression of GST Ya1 or GST Ya2 mRNA or CYP 1A1 protein in rats. Taken together, these findings demonstrate a difference between rats and mice in the potential involvement of AhR as related to VCD-induced ovotoxicity. Whereas, AhR appears to be involved in rats, no evidence for a similar role in mice was obtained. Overall, these findings point out that there can be mechanistic species differences in ovarian responses to xenobiotic chemicals. FAU - Thompson, Kary E AU - Thompson KE AD - Department of Physiology, The University of Arizona, College of Medicine, Tucson, AZ 85724-5051, USA. FAU - Bourguet, Shannon M AU - Bourguet SM FAU - Christian, Patricia J AU - Christian PJ FAU - Benedict, Jamie C AU - Benedict JC FAU - Sipes, I Glenn AU - Sipes IG FAU - Flaws, Jodi A AU - Flaws JA FAU - Hoyer, Patricia B AU - Hoyer PB LA - eng GR - ES06694/ES/NIEHS NIH HHS/United States GR - R01-ES08979/ES/NIEHS NIH HHS/United States GR - R01-ES09246/ES/NIEHS NIH HHS/United States GR - R01-HD38995/HD/NICHD NIH HHS/United States GR - T32 GM08400-10/GM/NIGMS NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Benzoflavones) RN - 0 (Carcinogens) RN - 0 (Cyclohexanes) RN - 0 (Cyclohexenes) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Aryl Hydrocarbon) RN - 0 (Vinyl Compounds) RN - 596C064IG4 (4-vinyl-1-cyclohexene dioxide) RN - 604-59-1 (alpha-naphthoflavone) RN - EC 3.4.22.- (Casp3 protein, mouse) RN - EC 3.4.22.- (Casp3 protein, rat) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.22.- (Caspases) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Benzoflavones/pharmacology MH - Carcinogens/*toxicity MH - Caspase 3 MH - Caspases/metabolism MH - Cell Count MH - Cyclohexanes/*toxicity MH - Cyclohexenes MH - Female MH - Follicular Atresia/drug effects MH - Gene Expression Regulation/drug effects MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Microscopy, Confocal MH - Ovarian Follicle/*drug effects/metabolism MH - RNA, Messenger/analysis/metabolism MH - Rats MH - Rats, Inbred F344 MH - Receptors, Aryl Hydrocarbon/analysis/*antagonists & inhibitors/genetics MH - Reverse Transcriptase Polymerase Chain Reaction MH - Species Specificity MH - Vinyl Compounds/*toxicity EDAT- 2005/02/16 09:00 MHDA- 2005/04/09 09:00 CRDT- 2005/02/16 09:00 PHST- 2004/05/12 00:00 [received] PHST- 2004/07/26 00:00 [accepted] PHST- 2005/02/16 09:00 [pubmed] PHST- 2005/04/09 09:00 [medline] PHST- 2005/02/16 09:00 [entrez] AID - S0041-008X(04)00362-X [pii] AID - 10.1016/j.taap.2004.07.010 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2005 Mar 1;203(2):114-23. doi: 10.1016/j.taap.2004.07.010.